1. Treatment Initiation and Selection in Newly Diagnosed CLL

3. Content Outline

4. The Patient Is at the Center of First-Line CLL Treatment Decisions

5. Understanding CLL Risk Stratification

6. Alliance A041202 Ibrutinib or Ibrutinib-Rituximab for Older Patients With CLL

7. Ibrutinib-Containing Therapy PFS in Older Patients

8. Alliance Study Grade ≥ 3 Adverse Events of Interest

9. E1912 Ibrutinib-Rituximab in Younger Patients

10. Can We Predict Who Will Experience Long-Term Remission?

11. Ibrutinib Toxicity, Young vs Old

12. Can Thoughtful Treatment Sequencing Reduce TLS Associated With Venetoclax?

13. Ibrutinib-Venetoclax Short-Term Follow-Up in Previously Untreated CLL

14. Careful Treatment Sequencing May Reduce Risk of TLS

15. 3-Year Follow-Up With Acalabrutinib

16. iLLUMINATE Study Design

17. Ibrutinib-Obinutuzumab Activity in Previously Untreated CLL

18. iLLUMINATE Grade ≥ 3 Toxicities of Interest

19. Let's Consider a Patient

20. Deciding When to Use Ibrutinib in Non-Del(17p) Previously Untreated CLL

21. Does the Patient Want Time-Limited or Continuous Therapy?

22. When to Consider Ibrutinib-Free First-Line Therapy

23. More Informed = Better Prepared to Decide

24. Key Considerations for First-Line Treatment Selection

25. Molecular Testing Remains an Unmet Need

26. Helping Patients Transition From Watchful Waiting to Definitive Therapy

27. Moving Beyond Chemotherapy Pros and Cons

28. Fitting Therapy to Patients

29. Key Takeaways

30. Abbreviations

31. Abbreviations (cont)